Bradford K. Berges, Ph.D. - Publications

Affiliations: 
2005 University of Pennsylvania, Philadelphia, PA, United States 
Area:
Molecular Biology

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Guerrero-Arguero I, Høj TR, Tass ES, Berges BK, Robison RA. A comparison of Chikungunya virus infection, progression, and cytokine profiles in human PMA-differentiated U937 and murine RAW264.7 monocyte derived macrophages. Plos One. 15: e0230328. PMID 32163514 DOI: 10.1371/Journal.Pone.0230328  0.358
2018 Fullwood RA, Low GM, Chase EP, Grasley M, Beal SS, McCrary IM, Daniels CW, Ingersoll K, Berges BK. The Kaposi's sarcoma-associated herpesvirus viral interleukin 6 gene affects metastasis and expression of B cell markers in a murine xenograft model. Plos One. 13: e0204947. PMID 30265712 DOI: 10.1371/Journal.Pone.0204947  0.328
2016 Benjamin R, Berges BK, Solis-Leal A, Igbinedion O, Strong CL, Schiller MR. TALEN gene editing takes aim on HIV. Human Genetics. PMID 27170155 DOI: 10.1007/S00439-016-1678-2  0.353
2016 Cornaby C, Tanner A, Stutz EW, Poole BD, Berges BK. Piracy on the molecular level: human herpesviruses manipulate cellular chemotaxis. The Journal of General Virology. 97: 543-60. PMID 26669819 DOI: 10.1099/Jgv.0.000370  0.374
2015 Tanner A, Hallam SJ, Nielsen SJ, Cuadra GI, Berges BK. Development of human B cells and antibodies following human hematopoietic stem cell transplantation to Rag2(-/-)γc(-/-) mice. Transplant Immunology. 32: 144-50. PMID 25843523 DOI: 10.1016/J.Trim.2015.03.002  0.35
2014 Horvat B, Berges BK, Lusso P. Recent developments in animal models for human herpesvirus 6A and 6B. Current Opinion in Virology. 9: 97-103. PMID 25462440 DOI: 10.1016/J.Coviro.2014.09.012  0.409
2014 Berges BK, Tanner A. Modelling of human herpesvirus infections in humanized mice. The Journal of General Virology. 95: 2106-17. PMID 25053560 DOI: 10.1099/Vir.0.067793-0  0.425
2014 Tanner A, Taylor SE, Decottignies W, Berges BK. Humanized mice as a model to study human hematopoietic stem cell transplantation. Stem Cells and Development. 23: 76-82. PMID 23962058 DOI: 10.1089/Scd.2013.0265  0.327
2013 Tanner A, Carlson SA, Nukui M, Murphy EA, Berges BK. Human herpesvirus 6A infection and immunopathogenesis in humanized Rag2⁻/⁻ γc⁻/⁻ mice. Journal of Virology. 87: 12020-8. PMID 24006442 DOI: 10.1128/Jvi.01556-13  0.401
2013 Sanchez FM, Berges BK. Characterization of HIV-1 infection in the humanized Rag2-/-γc-/- mouse model. Methods in Molecular Biology (Clifton, N.J.). 1031: 215-22. PMID 23824904 DOI: 10.1007/978-1-62703-481-4_24  0.432
2013 Sanchez FM, Cuadra GI, Nielsen SJ, Tanner A, Berges BK. Production and characterization of humanized Rag2-/-γc -/- mice. Methods in Molecular Biology (Clifton, N.J.). 1031: 19-26. PMID 23824882 DOI: 10.1007/978-1-62703-481-4_2  0.375
2011 Berges BK, Rowan MR. The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology. 8: 65. PMID 21835012 DOI: 10.1186/1742-4690-8-65  0.453
2011 Akkina R, Berges BK, Palmer BE, Remling L, Neff CP, Kuruvilla J, Connick E, Folkvord J, Gagliardi K, Kassu A, Akkina SR. Humanized Rag1-/-γc-/- mice support multilineage hematopoiesis and are susceptible to HIV-1 infection via systemic and vaginal routes Plos One. 6. PMID 21695116 DOI: 10.1371/Journal.Pone.0020169  0.417
2010 Berges BK, Akkina SR, Remling L, Akkina R. Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology. 397: 100-3. PMID 19922970 DOI: 10.1016/J.Virol.2009.10.034  0.417
2008 Berges BK, Akkina SR, Folkvord JM, Connick E, Akkina R. Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice. Virology. 373: 342-51. PMID 18207484 DOI: 10.1016/J.Virol.2007.11.020  0.372
2007 Berges BK, Wolfe JH, Fraser NW. Transduction of brain by herpes simplex virus vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 20-9. PMID 17164771 DOI: 10.1038/Sj.Mt.6300018  0.618
2006 Berges BK, Wheat WH, Palmer BE, Connick E, Akkina R. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-γc-/- (RAG-hu) mouse model Retrovirology. 3. PMID 17078891 DOI: 10.1186/1742-4690-3-76  0.41
2006 Berges BK, Yellayi S, Karolewski BA, Miselis RR, Wolfe JH, Fraser NW. Widespread correction of lysosomal storage in the mucopolysaccharidosis type VII mouse brain with a herpes simplex virus type 1 vector expressing beta-glucuronidase. Molecular Therapy : the Journal of the American Society of Gene Therapy. 13: 859-69. PMID 16515890 DOI: 10.1016/J.Ymthe.2005.12.017  0.62
2006 Berges B, Wheat W, Palmer B, Akkina R. HIV-1 infection and CD4 T cell depletion in humanized Rag2-/-yc-/- mice Retrovirology. 3: 1-1. DOI: 10.1186/1742-4690-3-S1-S73  0.438
2005 Berges BK, Wolfe JH, Fraser NW. Stable levels of long-term transgene expression driven by the latency-associated transcript promoter in a herpes simplex virus type 1 vector. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 1111-9. PMID 16122987 DOI: 10.1016/J.Ymthe.2005.06.478  0.627
2005 Berges BK, Gupta A, Wolfe JH, Fraser NW. 157. Quantitation of Long-Term Gene Expression from the HSV-1 Latency-Associated Promoter in the Mouse Brain Following Intracranial Injection Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.161  0.604
2004 Yellayi S, Berges B, Wolfe J, Vite C, Fraser N. 223. Delivery of HSV Based Vectors for Correction of CNS Pathology in Mucopolysaccharodosis Type vii (MPS vii) Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.166  0.632
2004 Berges BK, Wolfe JH, Fraser NW. 217. Widespread Distribution of Beta-Glucuronidase in the Mouse Brain Is Achieved after a Single Inoculation with a Neuroattenuated HSV Vector: Distribution Differs with Inoculation Site Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.159  0.6
Show low-probability matches.